2015
DOI: 10.1016/j.jaad.2015.06.059
|View full text |Cite
|
Sign up to set email alerts
|

Multiple primary melanomas among 16,570 patients with melanoma diagnosed at Kaiser Permanente Northern California, 1996 to 2011

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
4
1

Citation Types

17
63
5
1

Year Published

2016
2016
2024
2024

Publication Types

Select...
7

Relationship

1
6

Authors

Journals

citations
Cited by 56 publications
(86 citation statements)
references
References 11 publications
17
63
5
1
Order By: Relevance
“…One of these cases occurred in a patient with neurofibromatosis type 1, which may have represented a unique inherited predisposition [6] . Multiple primary cutaneous melanomas, however, are not uncommon, ranging from 0.2 to 8.6% of primary melanomas [7][8][9][10][11][12][13] . The observed numbers in most studies are well beyond those expected by chance alone [7-10, 12, 13] .…”
Section: Discussionmentioning
confidence: 99%
See 3 more Smart Citations
“…One of these cases occurred in a patient with neurofibromatosis type 1, which may have represented a unique inherited predisposition [6] . Multiple primary cutaneous melanomas, however, are not uncommon, ranging from 0.2 to 8.6% of primary melanomas [7][8][9][10][11][12][13] . The observed numbers in most studies are well beyond those expected by chance alone [7-10, 12, 13] .…”
Section: Discussionmentioning
confidence: 99%
“…The second melanoma in patients with two primaries tends to be thinner, on average, than the initial tumor [7][8][9][10][11][12][13] . In persons with multiple primary melanomas, Breslow thickness is the main determinant of prognosis [7][8][9][10][11][12][13] .…”
Section: Discussionmentioning
confidence: 99%
See 2 more Smart Citations
“…58 Melanoma survivors are at increased risk of developing a second primary cancer at another site, especially skin cancers, but also cancers of the bone, soft tissue, colon and rectum, female breast, kidney, prostate, thyroid, non-Hodgkin lymphoma, and chronic lymphocytic leukemia. 59,60 In one study, melanoma patients receiving a BRAF inhibitor for metastatic disease (vemurafenib) had a 26% chance of developing a SCC within a median timeframe of approximately 8 weeks; most of the SCCs were keratoacanthomatype, which generally have a good prognosis.…”
Section: Risk Of Skin Cancer Among Cancer Survivorsmentioning
confidence: 99%